“There are many new and exciting things being done in Alzheimer�s research,” said Dr. Michael J. Cauchy, M.D., Ph.
D. “We�re seeing a lot of changes that are going to change how we understand and care for the disease, how we think about prevention and care.
We�re also seeing more and more discoveries in the field of Alzheimer�tology.”
Cauchy is one of the leading experts in Alzheimer`s disease research, with more than 30 years of clinical experience in Alzheimer research and treatment.
He�s the founding director of the Alzheimer`S Disease Research Institute (ADRI), a $50 million multi-institutional consortium dedicated to the development of advanced Alzheimer�dysciency treatments.
Cauchys work is focused on Alzheimer�mation.
He and other researchers at ADRI are developing treatments to prevent and manage the progression of Alzheimer`mation, which affects about 1 in 10 people.
He also recently led a study published in the journal, PLOS ONE.
Cauchuys study involved using gene sequencing to identify the genes involved in Alzheimer”s disease.
Researchers used that information to determine which genes could be targeted for treatment in order to improve Alzheimer�disorder outcomes.
“This is a very exciting time in Alzheimer disease research because it�s a new and very exciting area of research,” Cauchuies co-author David L. Brown, M, Ph.
P. said in a statement.
“This is really exciting work that we can leverage to advance our understanding of the disease.”
Researchers also discovered the gene responsible for the development and progression of Alzheimers disease, a gene known as BRAF.
BRAF is a gene that helps control the body�s production of the neurotransmitter serotonin.
BRAF plays an important role in how Alzheimer�z is affected, as the disease affects the brain and affects memory and thinking.
Researchers believe that using BRAF gene sequencing can help them develop new drugs to treat Alzheimer disease.
Scientists at the ADRI, including Brown, have been working to develop and test drugs to prevent or slow the progression and progression in the brains of people with Alzheimer�a disease.
Scientists have also been working with pharmaceutical companies to develop drugs to slow the rate of the development in the brain of people who have Alzheimernas disease, a form of Alzheimer’s Disease.
Dr. Michael Cauchias study was funded by the National Institute of Neurological Disorders and Stroke (NINDS) NIH grant P50AG054985, and the Robert Wood Johnson Foundation Grant to the Alzheimer�Research Institute.
The study was published online in PLOS One on March 26.
To learn more about Alzheimer�ts disease, visit the Alzheimer’s Association website at http://www.aia.org/news/news_news_aia_luckey_mike_nelson/aia-luckeys-health_disease_news.html or read the news release at http:/ / news.apa.org/.
You can also follow APA on Twitter: @APAHealth, @HealthcareAlert, #HealthAlertNews, APANews, and @AMA_News.